Skip to main navigation

+44 (0)20 8154 4600
info@achillestx.com

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Press Releases

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Year

All News
2023
2022
2021
2020
2019
2018
2017
2016

Nov 8 2022

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Read More +

Oct 6 2022

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

Read More +

Aug 9 2022

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Read More +

Jul 21 2022

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

Read More +

Jun 30 2022

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

Read More +

Jun 21 2022

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

Read More +

May 10 2022

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Read More +

May 9 2022

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

Read More +

May 4 2022

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

Read More +

May 3 2022

Achilles Therapeutics to Present at Upcoming Conferences

Read More +

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Next page
Last page

Print Page

RSS Feeds

Email Alerts

Contact IR

Home
About Us
Science
Publications
Pipeline
Investors & Media
Work with us
Contact

UK Headquarters:
Achilles Therapeutics plc
245 Hammersmith Road
London
W6 8PW, UK

US Headquarters:
Achilles Therapeutics US, Inc.
401 N. Broad Street
Suite M121
Philadelphia, PA 19108

+44 (0)20 8154 4600
info@achillestx.com

© Copyright - Achilles Therapeutics plc.

Achilles Therapeutics plc (13027460) is registered in England and Wales. The registered office is at 245 Hammersmith Road, London, W6 8PW.

Privacy & Cookie Policy

Terms & Conditions